Title:
AUTOIMMUNE DISEASE THERAPEUTIC AGENT INCLUDING OLIGONUCLEOTIDE THAT SELECTIVELY BINDS TO IFN-γ, AND SAID OLIGONUCLEOTIDE
Document Type and Number:
WIPO Patent Application WO/2023/063242
Kind Code:
A1
Abstract:
One purpose of the present invention is to provide an autoimmune disease therapeutic agent that can selectively inhibit IFN-γ, does not have a risk of biological contamination, and can be stored at room temperature. Provided is an autoimmune disease therapeutic agent including, as an active ingredient, a DNA oligonucleotide that has the nucleic acid sequence indicated in any of SEQ ID NO:1-3 and selectively binds to IFN-γ. Provided as a separate aspect is a DNA oligonucleotide that has the nucleic acid sequence indicated in any of SEQ ID NO:1-3 and has an autoimmune disease therapeutic effect by selectively binding to IFN-γ.
Inventors:
HARADA KAORI (JP)
HORI MIYUKI (JP)
HORI MIYUKI (JP)
Application Number:
PCT/JP2022/037560
Publication Date:
April 20, 2023
Filing Date:
October 07, 2022
Export Citation:
Assignee:
TAGCYX BIOTECHNOLOGIES INC (JP)
International Classes:
C12N15/115; A61K31/711; A61K47/55; A61P1/00; A61P1/16; A61P3/10; A61P9/00; A61P13/10; A61P15/00; A61P17/00; A61P17/06; A61P17/14; A61P19/00; A61P19/02; A61P25/28; A61P27/02; A61P27/04; A61P29/00; A61P37/02; A61P37/06; A61P37/08; C07K14/57
Domestic Patent References:
| WO2016143700A1 | 2016-09-15 |
Foreign References:
| JP2008528569A | 2008-07-31 | |||
| JP2020519562A | 2020-07-02 | |||
| JP2017506243A | 2017-03-02 | |||
| JP2021100408A | 2021-07-08 | |||
| JP2018506284A | 2018-03-08 | |||
| CN112813070A | 2021-05-18 |
Attorney, Agent or Firm:
FUJITA, Takaharu (JP)
Download PDF:
Previous Patent: ROTARY ELECTRIC MACHINE
Next Patent: SCROLL COMPRESSOR AND METHOD FOR MANUFACTURING SAME
Next Patent: SCROLL COMPRESSOR AND METHOD FOR MANUFACTURING SAME